Functional outcome and prognostic factors in anti-Jo1 patients with antisynthetase syndrome

Arthritis research & therapy (Impact Factor: 3.75). 10/2013; 15(5):R149. DOI: 10.1186/ar4332
Source: PubMed


The aims of this present study were firstly to assess the outcome, including functional course, in anti-Jo1 positive patients with antisynthetase syndrome (ASS), and secondly to determine predictive parameters of poor outcome in these patients.
The medical records of 86 consecutive anti-Jo1 patients with ASS were reviewed in 4 academic centers.
13 patients (15.1%) achieved remission of ASS, whereas 55 (63.9%) improved and 18 (20.9%) deteriorated in their clinical status. Both steroid and cytotoxic drugs could be discontinued in only 4.7% of patients. ASS was associated with decreased quality of life at long-term follow-up: only 69.2% of patients considered to be in remission experienced a return to previous normal activities; and 24.7% of other patients with non-remitting ASS still had a marked reduction of activities (as shown by the disability scale of the Health Assessment Questionnaire). Decreased quality of life was further due to calcinosis cutis (8.1%) and adverse effects of steroid therapy (36%). Factors associated with ASS deterioration were older age, pulmonary and esophageal involvement, calcinosis cutis and cancer. Higher anti-Jo1 levels were further associated with disease severity in ASS patients.
The present study shows high morbidity related to ASS. Furthermore, we suggest that patients with predictive factors of ASS deterioration may require more aggressive therapy. Our findings also suggest that in anti-Jo1 patients with severe esophageal manifestations, combined high dose steroids and intravenous immunoglobulins might be proposed as the first line therapy. Finally, as cancer occurred in 14% of anti-Jo1 patients, our findings underscore that the search for cancer should be performed in these patients.

Download full-text


Available from: Pierre‐Yves Hatron, Mar 20, 2015
9 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective To assess the long-term outcome in polymyositis (PM) and dermatomyositis (DM), with particular emphasis to mortality and influence of treatment. Methods Diagnosis was based according to the Bohan and Peter’s criteria. Patients have been followed by a standardised protocol. Deaths were registered and causes of death ascertained. Survival probability at 5 and 10 years was estimated according to Kaplan-Meier method, in the overall series and by diagnostic group and initial treatment. Mortality hazard ratios (95% CI) for major clinical and demographic features were estimated through univariate and multivariate Cox proportional hazard models. Results 91 patients (43 PM and 48 DM) were available for the study. Baseline characteristics were not different from those previously reported. Twenty-two patients (24%) died after a median follow-up of 8.7 years. As for idiopathic myositis, the survival probabilities at 5- and 10-years from the diagnosis were 96.2% and 88.8% for PM respectively; and 93.9% for DM, whereas a higher mortality was documented for cancer-associated and overlap-myositis myositis. Male sex [HR = 2.4, 95% CI 1.0 to 5.6], heart involvement (HR = 1.8), interstitial lung disease (HR = 2.3) and arthritis (HR = 1.8), increased the risk of mortality, these risk excesses were confirmed in multivariate analysis. Independently of these features, a higher mortality was documented for patients treated with glucocorticoids (HR = 2.3) or immunosuppressant (HR = 2.1) versus patients treated with immunoglobulin. Conclusion Our study, with longitudinal and statistical analyses, suggests that survival has considerably increased in patients with PM/DM. Prognostic factors for mortality are male sex, heart and lung involvement. Immunoglobulin treatment, intravenously or subcutaneously, is associated with a better survival.
    Autoimmunity Reviews 10/2014; 13(10). DOI:10.1016/j.autrev.2014.08.023 · 7.93 Impact Factor